Sarah Tasian Laboratory
Led by Sarah K. Tasian, MD, researchers in the Tasian Laboratory are focused on using molecular and genomic approaches to identify targeted cancer treatments and immunotherapies to treat children with high-risk acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The long-term goal of the research conducted in this laboratory is to develop better therapies, improve cure rates and minimize toxicities for children with leukemia.
Efficacy of JAK/STAT inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015 Mar 12;125(11):1759-67.
Maude SL, Dolai S, Delgado-Martin C, Vincent TL, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT.
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children’s Oncology Group Phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct;62(10):1717-24.
Loh ML, Tasian SK, Rabin KR, Brown PA, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM.
Histology of testicular biopsies obtained for an experimental fertility preservation protocol in boys with cancer. J Urol. 2015 Nov;194(5):1420-4.
Pietzak EJ, Tasian GE, Tasian SK, Brinster RL, Carlson C, Ginsberg JP, Kolon TF.